Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Vaxart (NASDAQ:VXRT), maintaining a $4 price target.
September 07, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $4.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Vaxart's stock. The maintained price target of $4 also suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100